Anti‐VEGF therapy was linked to lower risks of retinal detachment (0.36; 0.27–0.50), fewer surgical interventions (0.38; 0.22–0.65), and a lower risk of myopia (0.67; 0.54–0.82). The gene discussed is VEGFA; the disease is myopia.